ADC Therapeutics

101 articles with ADC Therapeutics

• ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16th Annual International Conference on Malignant Lymphoma

  6/18/2021

  ADC Therapeutics Presents Updated ZYNLONTA™ (loncastuximab tesirine-lpyl) Clinical Data at 16 th Annual International Conference on Malignant Lymphoma

• ADC Therapeutics Shareholders Approve All Resolutions at the Annual General Meeting

  6/11/2021

  ADC Therapeutics SA today announced that shareholders approved all of the resolutions as proposed by the Board of Directors at yesterday's Annual General Meeting.

• ADC Therapeutics Announces Presentations at the 16th Annual International Conference on Malignant Lymphoma

  6/9/2021

  ADC Therapeutics SA announced that abstracts on camidanlumab tesirine and ZYNLONTA™ have been selected for presentation at the 16th Annual International Conference on Malignant Lymphoma, which is being held virtually June 18-22, 2021.

• ADC Therapeutics to Present at Jefferies Virtual Healthcare Conference

  5/27/2021

  ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021, at 8:30 a.m. ET.

• ADC Therapeutics Announces Online Publication of Camidanlumab Tesirine Phase 1 Results in The Lancet Haematology

  5/26/2021

  Camidanlumab tesirine (Cami) demonstrated anti-tumoral activity response rate in 86% of Hodgkin lymphoma patients at dose currently being evaluated in ongoing pivotal Phase 2 trial

• Avid Bioservices to Serve as Commercial Manufacturer for ADC Therapeutics’ ZYNLONTA™ (Loncastuximab Tesirine-Lpyl)

  5/25/2021

  ZYNLONTA™ Recently Approved as First and Only CD19-Targeted Antibody Drug Conjugate for Single-Agent Treatment for Adult Patients with Relapsed or Refractory (r/r) Diffuse Large B-cell Lymphoma (DLBCL)

• ADC Therapeutics Announces Presentations at the 2021 ASCO Annual Meeting

  5/19/2021

  Posters to highlight ZYNLONTA ™ LOTIS-2 subgroup analyses, ZYNLONTA ™ LOTIS-5 confirmatory trial and Cami in advanced solid tumors

• ADC Therapeutics Announces Receipt of $50 Million Second Tranche of Convertible Credit Facility with Deerfield

  5/17/2021

  ADC Therapeutics SA, a commercial-stage biotechnology company leading the development of novel antibody drug conjugates to treat hematological malignancies and solid tumors, announced the receipt of the $50 million second tranche under its convertible credit facility with Deerfield Partners, L.P. and certain of its affiliates.

• ADC Therapeutics Announces Online Publication of LOTIS-2 Results in The Lancet Oncology

  5/12/2021

  Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2 ZYNLONTA ™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with relapsed or refractory DLBCL

• 

  FDA Action Alert: Heron, Apellis, Sanofi, Merck and ADC

  5/10/2021

  May is a busy month for the U.S. Food and Drug Administration (FDA)’s calendar for new drug reviews. Here’s a look.

• ADC Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

  5/6/2021

  - ZYNLONTA™ (loncastuximab tesirine-lpyl) granted accelerated FDA approval for patients with relapsed or refractory diffuse large B-cell lymphoma - Commercial launch progressing well; orders shipped - NCCN guidelines category 2A recommendation to reflect the broad FDA indication - Company to host conference call today at 8:30 a.m. EDT

• 

  With Approvals in Hand, These Three New Drugs Are Hitting the Market

  5/6/2021

  Less than two weeks after receiving the greenlight for Zynlonta under accelerated approval, ADC Therapeutics has launched its treatment for adult patients with relapsed or refractory diffuse large B-cell lymphoma.

• ADC Therapeutics to Participate in May Investor Conferences

  5/4/2021

  ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at two virtual investor conferences in May.

• ADC Therapeutics to Host First Quarter 2021 Financial Results Conference Call on May 6, 2021

  4/29/2021

  ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that it will host a conference call and live webcast on Thursday, May 6, 2021 at 8:30 a.m. EDT to report financial results for the first quarter 2021 and provide business updates.

• ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

  4/23/2021

  First and only CD19-targeted antibody drug conjugate (ADC) as a single-agent treatment for adult patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL) ZYNLONTA addresses an unmet need across a broad population of third-line (3L)+ r/r patients, including patients with DLBCL not otherwise specified, DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma

• Overland ADCT BioPharma Appoints Eric Koo as Chief Executive Officer

  4/6/2021

  Overland ADCT BioPharma, a joint venture created by Overland Pharmaceuticals and ADC Therapeutics SA (NYSE: ADCT), today announced the appointment of Eric Koo, BSc, MBA, as Chief Executive Officer.

• ADC Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results and Provides Business Updates

  3/18/2021

  - Lonca BLA accepted by FDA with priority review; PDUFA date May 21, 2021 - Commercial, medical affairs, CMC and support functions prepared for potential Lonca approval - Updated data for lead programs Lonca and Cami presented at American Society of Hematology (ASH) Annual Meeting in December 2020

•  ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021

  3/11/2021

    ADC Therapeutics to Host Fourth Quarter and Year-End 2020 Financial Results Conference Call on March 18, 2021

• ADC Therapeutics to Participate in Cowen 41st Annual Health Care Conference

  2/25/2021

  ADC Therapeutics to Participate in Cowen 41 st Annual Health Care Conference

• ADC Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Day

  2/5/2021

  ADC Therapeutics SA (NYSE:ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors, announced today that Chris Martin, Chief Executive Officer, will participate in a fireside chat at Guggenheim Healthcare Talks 2021 Oncology Day